Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year. » Read More
But St. Louis Fed President James Bullard wouldn't be firm, saying he would like to hike rates on good economic news.
Jim Cramer says executive embarrassment and presidential candidate tweets won’t solve the EpiPen problem.
Some of the names on the move ahead of the open.
Jim Cramer says it's time for Apple to put its massive $231 billion cash hoard to work, and buy this company.
Shares of St. Jude Medical briefly fell more than 8 percent Thursday after Muddy Waters Capital announced the firm is short the stock.
Shares of two jewelers were on the move Thursday after reporting quarterly earnings.
Did you predict that oil would bounce in 2016? Nice! Did you attempt to cash in by buying the biggest oil ETF? Uh-oh.
As political pressure appears to mount on biotech stocks, some technical analysts say the foundation for a bounce may be building.
Three months after Wal-Mart said it would move faster to cut prices, Dollar General said it has taken a similar approach.
Europe's pursuit of companies like Apple for under-paid taxes highlights a major problem with few prospects for a global solution.
Call it crowd-sourcing for algorithmic trading.
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Pacific Crest reiterates its overweight rating on Palo Alto Networks.
American banks spent the second quarter crying all the way to the, well, bank.
Shares of Mylan held slightly lower in afternoon trade, giving up earlier gains of more than 4 percent.
Shares of Workday climbed 7 percent after the enterprise software company reported an increase in subscriber revenue.
Get the best of CNBC in your inbox